{"nctId":"NCT00770874","briefTitle":"Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer","startDateStruct":{"date":"2008-09"},"conditions":["Cervical Cancer"],"count":375,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: S-1 + Cisplatin (arm A)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin (arm B)"]}],"interventions":[{"name":"S-1 + Cisplatin (arm A)","otherNames":[]},{"name":"Cisplatin (arm B)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with histologically proven cervical carcinoma (All histological subtype will be included).\n* Patients who have stage IVB, recurrent or persistent disease.\n* Patients who are not amenable to curative treatment with surgery and/or radiotherapy.\n* Patients who have not received chemotherapy or chemoradiotherapy after diagnosis of recurrent, persistent, or stage IVB disease.\n* If the patient have received chemotherapy, radiotherapy or chemoradiotherapy as previous treatment, following interval must have elapsed from the last administration of treatment:\n\n  1. Chemotherapy: 21 days\n  2. Radiotherapy: 21 days\\*\n  3. Chemoradiotherapy: 42 days\\*\n\nIf there have been residual disease in previously irradiated field and without disease progression since the (chemo) radiotherapy, 90 days must have elapsed after the last administration of irradiation.\n\n* Patients who have adequate hematologic, hepatic and renal functions as defined below:\n\n  * Hemoglobin: ≥ 8.0 g/dL\n  * Neutrophil count: ≥ 2,000/mm\\^3\n  * Platelet count: ≥ 100,000/mm\\^3\n  * Total serum bilirubin: ≤ 1.5 times the upper limits of normal (ULN)\n  * AST (GOT), ALT (GPT): ≤ 2.5 times the ULN. If abnormal values are associated with hepatic metastasis: ≤ 5.0 times the ULN\n  * Serum creatinine: ≤ ULN or creatinine clearance: ≥ 50 ml/min\n* Patients who have an ECOG performance status : 0-1.\n* Age: ≥ 20 years old.\n* Patients who can take pills orally.\n* Patients who signed the written consent form.\n\nExclusion Criteria:\n\n* Patients who have known hypersensitivity to 5-FU or Cisplatin.\n* Patients who are receiving concomitant treatment with drugs interacting with S-1.\n* Patients who are receiving concomitant treatment with drugs interacting with Cisplatin.\n* Patients who were administered other investigational products within 30 days before the initiation of study treatment.\n* Patients who were previously treated with S-1.\n* Patients who had received platinum-containing chemotherapy or chemoradiotherapy and whose disease progressed during the therapy.\n* Patients who suffer from active infection (e.g. fever ≥ 38°C).\n* Patients who have serious complications.\n* Patients with bleeding which requires hemostasis treatment.\n* Patients with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.\n* Patients with uncontrolled pleural effusion and/or ascites requiring drainage at least twice a week.\n* Patients with symptomatic brain metastasis or history of brain metastasis.\n* Patients who have unmanageable bowel movement (ex. Watery stool, chronic constipation).\n* Patients with active double cancer.\n* Patients who are pregnant or lactating.\n* Patients who are considered to be inappropriate to the subject of this study by the investigator.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null},{"groupId":"OG001","value":"19.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival, Safety","description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":72,"n":188},"commonTop":["Nausea","Decreased appetite","Haemoglobin decreased","Neutrophil count decreased","Fatigue"]}}}